WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 202701
Description: Resveratrol (also known as SRT-501) is a phytoalexin derived from grapes and other food products with antioxidant and potential chemopreventive activities. Resveratrol induces phase II drug-metabolizing enzymes (anti-initiation activity); mediates anti-inflammatory effects and inhibits cyclooxygenase and hydroperoxidase functions (anti-promotion activity); and induces promyelocytic leukemia cell differentiation (anti-progression activity), thereby exhibiting activities in three major steps of carcinogenesis. This agent may inhibit TNF-induced activation of NF-kappaB in a dose- and time-dependent manner.
MedKoo Cat#: 202701
Chemical Formula: C14H12O3
Exact Mass: 228.07864
Molecular Weight: 228.24
Elemental Analysis: C, 73.67; H, 5.30; O, 21.03
Synonym: trans-Resveratrol; SRT501; SRT-501; SRT 501; RM1812; RM-1812; RM 1812; CA1201; CA-1201; CA 1201; Resvida; Vineatrol 20M.
IUPAC/Chemical Name: (E)-5-(4-hydroxystyryl)benzene-1,3-diol
InChi Key: LUKBXSAWLPMMSZ-OWOJBTEDSA-N
InChi Code: InChI=1S/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1+
SMILES Code: OC1=CC(/C=C/C2=CC=C(O)C=C2)=CC(O)=C1
Appearance: Light yellow solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: soluble in DMSO, not soluble in water.
Shelf Life: >10 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
|Biological target:||Resveratrol (trans-Resveratrol; SRT501) is a natural polyphenolic phytoalexin that has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase (IC50 0.8 nM), IKKβ (IC50 1 μM) , DNA polymerase α (IC50 3.3 μM), and DNA polymerase δ (5 μM).|
|In vitro activity:||In order to investigate the antiviral effects of RES against ZIKV, virus replication inhibition was determined in cells treated with different concentrations of RES, while the mock-treated cells were used as control. Huh7 cells were mock-treated or treated with different concentrations of RES (20 µM, 50 µM, 80 µM, and 100 µM) prior and post ZIKV infection at an MOI of 1. After 48 h, the supernatants of the non- and RES-treated cell cultures were harvested. The supernatants were used to infect Vero cells for the focusforming assay and the qRT-PCR assay. Treatment of cells with 20 µM, 50 µM, 80 µM and 100 µM of RES reduced the number of foci formed by 25%, 76%, 93% (1 log) and 97% (1 log), respectively (Fig. 2A,B). Correspondingly, ZIKV mRNA copy numbers were significantly reduced by the RES treatment (20 µM; 25% virus reduction, 50 µM; 92% [1 log] virus reduction, 80 µM; 96% [1 log] virus reduction, 100 µM; 98% [2 log] virus reduction) (Fig. 2C), suggesting the inhibitory effects of RES against ZIKV replication. Sci Rep. 2019; 9: 14336. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6778103/|
|In vivo activity:||It was hypothesized that resveratrol exerts anti-proliferation, anti-oxidant, and anti-inflammation effects during the progression of HPH. To verify the hypothesis, long-term gavage administration of resveratrol was explored in chronic hypoxia exposed rats. After 28 days hypoxia exposure, the myocytes of right ventricle in hypoxia group was significantly enlarged versus the normoxic groups (Figure 1a, b; P<0.01). Resveratrol administration notably inhibited the hypertrophy of myocytes of right ventricle after chronic hypoxia (Figure 1a, b; P<0.01). There was no significant difference found in the two normoxic groups (Figure 1a, b). Accordingly, hypoxia exposure also markedly increased RVHI versus the normoxic groups (Figure 1c; P<0.01), and resveratrol treatment significantly decreased the elevation of RVHI (Figure 1c, P<0.01). Resveratrol administration significanlty decreased both indices of pulmonary arterial structure remodeling (P<0.01, Figure 2b, c). Chronic hypoxia resulted in plentiful infiltration of neutrophils in rat lungs compared to the normoxic groups (P<0.01, Figure 3aC, b). However, resveratrol treatment significantly reduced the infiltration of neutrophils in rat lungs (P<0.01,Figure 3aD, b). Conclusively, our results showed that treatment with resveratrol prevented the development of pulmonary hypertension induced by chronic hypoxia. Int J Med Sci. 2016; 13(12): 942–954. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5165688/|
|Solvent||Max Conc. mg/mL||Max Conc. mM|
The following data is based on the product molecular weight 228.24 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
|Formulation protocol:||1. Xu D, Li Y, Zhang B, Wang Y, Liu Y, Luo Y, Niu W, Dong M, Liu M, Dong H, Zhao P, Li Z. Resveratrol alleviate hypoxic pulmonary hypertension via anti-inflammation and anti-oxidant pathways in rats. Int J Med Sci. 2016 Nov 23;13(12):942-954. doi: 10.7150/ijms.16810. PMID: 27994500; PMCID: PMC5165688. 2. Mohd A, Zainal N, Tan KK, AbuBakar S. Resveratrol affects Zika virus replication in vitro. Sci Rep. 2019 Oct 4;9(1):14336. doi: 10.1038/s41598-019-50674-3. PMID: 31586088; PMCID: PMC6778103. 3. Feng H, Mou SQ, Li WJ, Zhang N, Zhou ZY, Ding W, Bian ZY, Liao HH. Resveratrol Inhibits Ischemia-Induced Myocardial Senescence Signals and NLRP3 Inflammasome Activation. Oxid Med Cell Longev. 2020 Aug 25;2020:2647807. doi: 10.1155/2020/2647807. PMID: 32908628; PMCID: PMC7468658.|
|In vitro protocol:||1. Xu D, Li Y, Zhang B, Wang Y, Liu Y, Luo Y, Niu W, Dong M, Liu M, Dong H, Zhao P, Li Z. Resveratrol alleviate hypoxic pulmonary hypertension via anti-inflammation and anti-oxidant pathways in rats. Int J Med Sci. 2016 Nov 23;13(12):942-954. doi: 10.7150/ijms.16810. PMID: 27994500; PMCID: PMC5165688. 2. Mohd A, Zainal N, Tan KK, AbuBakar S. Resveratrol affects Zika virus replication in vitro. Sci Rep. 2019 Oct 4;9(1):14336. doi: 10.1038/s41598-019-50674-3. PMID: 31586088; PMCID: PMC6778103.|
|In vivo protocol:||1. Xu D, Li Y, Zhang B, Wang Y, Liu Y, Luo Y, Niu W, Dong M, Liu M, Dong H, Zhao P, Li Z. Resveratrol alleviate hypoxic pulmonary hypertension via anti-inflammation and anti-oxidant pathways in rats. Int J Med Sci. 2016 Nov 23;13(12):942-954. doi: 10.7150/ijms.16810. PMID: 27994500; PMCID: PMC5165688. 2. Feng H, Mou SQ, Li WJ, Zhang N, Zhou ZY, Ding W, Bian ZY, Liao HH. Resveratrol Inhibits Ischemia-Induced Myocardial Senescence Signals and NLRP3 Inflammasome Activation. Oxid Med Cell Longev. 2020 Aug 25;2020:2647807. doi: 10.1155/2020/2647807. PMID: 32908628; PMCID: PMC7468658.|
1: ÂŠvajger U, Jeras M. Anti-inflammatory effects of resveratrol and its potential use in therapy of immune-mediated diseases. Int Rev Immunol. 2012 Jun;31(3):202-22. Review. PubMed PMID: 22587021.
2: Whitlock NC, Baek SJ. The anticancer effects of resveratrol: modulation of transcription factors. Nutr Cancer. 2012;64(4):493-502. Epub 2012 Apr 6. Review. PubMed PMID: 22482424; PubMed Central PMCID: PMC3349800.
3: Juan ME, Alfaras I, Planas JM. Colorectal cancer chemoprevention by trans-resveratrol. Pharmacol Res. 2012 Jun;65(6):584-91. Epub 2012 Mar 28. Review. PubMed PMID: 22465196.
4: Turan B, Tuncay E, Vassort G. Resveratrol and diabetic cardiac function: focus on recent in vitro and in vivo studies. J Bioenerg Biomembr. 2012 Apr;44(2):281-96. Review. PubMed PMID: 22437738.
5: Timmers S, Auwerx J, Schrauwen P. The journey of resveratrol from yeast to human. Aging (Albany NY). 2012 Mar;4(3):146-58. Review. PubMed PMID: 22436213; PubMed Central PMCID: PMC3348475.
6: Aluyen JK, Ton QN, Tran T, Yang AE, Gottlieb HB, Bellanger RA. Resveratrol: potential as anticancer agent. J Diet Suppl. 2012 Mar;9(1):45-56. Review. PubMed PMID: 22432802.
7: Nakata R, Takahashi S, Inoue H. Recent advances in the study on resveratrol. Biol Pharm Bull. 2012;35(3):273-9. Review. PubMed PMID: 22382311.
8: Lopez-Lluch G, Cruz-Calvo SS, Navas P. Resveratrol in cancer: cellular and mitochondrial consequences of proton transport inhibition. Curr Pharm Des. 2012;18(10):1338-44. Review. PubMed PMID: 22360556.
9: Li H, Xia N, FÃ¶rstermann U. Cardiovascular effects and molecular targets of resveratrol. Nitric Oxide. 2012 Feb 15;26(2):102-10. Epub 2012 Jan 4. Review. PubMed PMID: 22245452.
10: Scott E, Steward WP, Gescher AJ, Brown K. Resveratrol in human cancer chemoprevention--choosing the 'right' dose. Mol Nutr Food Res. 2012 Jan;56(1):7-13. doi: 10.1002/mnfr.201100400. Epub 2011 Oct 7. Review. PubMed PMID: 22218912.
11: Li F, Gong Q, Dong H, Shi J. Resveratrol, a neuroprotective supplement for Alzheimer's disease. Curr Pharm Des. 2012;18(1):27-33. Review. PubMed PMID: 22211686.
12: Mullin GE. Red wine, grapes, and better health--resveratrol. Nutr Clin Pract. 2011 Dec;26(6):722-3. Review. PubMed PMID: 22205561.
13: Frombaum M, Le Clanche S, Bonnefont-Rousselot D, Borderie D. Antioxidant effects of resveratrol and other stilbene derivatives on oxidative stress and *NO bioavailability: Potential benefits to cardiovascular diseases. Biochimie. 2012 Feb;94(2):269-76. Epub 2011 Nov 22. Review. PubMed PMID: 22133615.
14: Piotrowska H, Kucinska M, Murias M. Biological activity of piceatannol: leaving the shadow of resveratrol. Mutat Res. 2012 Jan-Mar;750(1):60-82. Review. PubMed PMID: 22108298.
15: Yu W, Fu YC, Wang W. Cellular and molecular effects of resveratrol in health and disease. J Cell Biochem. 2012 Mar;113(3):752-9. doi: 10.1002/jcb.23431. Review. PubMed PMID: 22065601.
16: Amri A, Chaumeil JC, Sfar S, Charrueau C. Administration of resveratrol: What formulation solutions to bioavailability limitations? J Control Release. 2012 Mar 10;158(2):182-93. Epub 2011 Sep 25. Review. PubMed PMID: 21978644.
17: Duntas LH. Resveratrol and its impact on aging and thyroid function. J Endocrinol Invest. 2011 Nov;34(10):788-92. Epub 2011 Sep 23. Review. PubMed PMID: 21946130.
18: Chu LM, Lassaletta AD, Robich MP, Sellke FW. Resveratrol in the prevention and treatment of coronary artery disease. Curr Atheroscler Rep. 2011 Dec;13(6):439-46. Review. Erratum in: Curr Atheroscler Rep. 2011 Dec;13(6):508. PubMed PMID: 21870059.
19: Dolinsky VW, Dyck JR. Calorie restriction and resveratrol in cardiovascular health and disease. Biochim Biophys Acta. 2011 Nov;1812(11):1477-89. Epub 2011 Jul 1. Review. PubMed PMID: 21749920.
20: Vang O, Ahmad N, Baile CA, Baur JA, Brown K, Csiszar A, Das DK, Delmas D, Gottfried C, Lin HY, Ma QY, Mukhopadhyay P, Nalini N, Pezzuto JM, Richard T, Shukla Y, Surh YJ, Szekeres T, Szkudelski T, Walle T, Wu JM. What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS One. 2011;6(6):e19881. Epub 2011 Jun 16. Review. PubMed PMID: 21698226; PubMed Central PMCID: PMC3116821.
Resveratrol new formulation: Sirtris Pharmaceuticals is currently deeloping a resveratrol formulation, called SRT501, which is a proprietary formulation of resveratrol, a polyphenolic phytoalexin derived from grapes and other food products with potential antioxidant, anti-obesity, antidiabetic and chemopreventive activities. Resveratrol may activate sirtuin subtype 1 (SIRT-1). SIRT1 activation has been reported to inhibit tumorigenesis and tumor cell proliferation. SIRT-1 is a member of the silent information regulator 2 (SIR2) (or sirtuin) family of enzymes that plays an important role in mitochondrial activity and acts as a protein deacetylase. SIRT1 appears to be involved in the regulation of numerous transcription factors such as Nf-kB and p53. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus) .
SRT501 is Sirtris's proprietary formulation of resveratrol with improved bioavailability. In Phase I human clinical trials, SRT501 was found to be safe and well tolerated. In Phase II human clinical trials, SRT501 also lowered glucose and improved insulin sensitivity in patients with Type 2 Diabetes. Sirtris are currently testing SRT501 in a Phase II trial in oncology; new patient enrollment is currently suspended. see http://www.sirtrispharma.com/pipeline-SRT501.html.